Prescription charge changes in England

16 March 2009

From April 1, changes will be made to National Health Service prescription charges and some dental treatments in England. Also the value of optical vouchers will also increase by an overall 2%.

The prescription charge exemption for people being treated for cancer, the effects of this disease or that of its treatment also comes into force from April 1. This new scheme will benefit up to 150,000 people already diagnosed with cancer, who might otherwise pay around GBP100 ($140) a year in prescription charges.

Prescription charges will increase by 10 pence from GBP7.10 to GBP7.20, also effective April 1.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Evaxion

A TechBio company that specializes in developing personalized vaccines and immunotherapies through its advanced AI-Immunology™ platform. The company bridges artificial intelligence technology, bioinformatics, and drug development to bring novel immunotherapies to patients facing cancer and infectious diseases.